PRE-MARKET CHINESE STOCK NEWS

Beijing Biostar Pharmaceuticals' plan to issue 25 million shares at HKD 4.00 each may dilute existing shareholder value but is aimed at raising capital, which could signal potential growth initiatives or financial challenges.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

PBoC injects CNY 500mln via 7-day reverse repos with the rate maintained at 1.40%

PBoC sets USD/CNY mid-point at 6.8502 vs exp. 6.8138 (prev. 6.8487)

PRE-MARKET CHINESE STOCK NEWS

US VP Vance expressed concern to tech CEOs over new AI models which can autonomously find software vulnerabilities, WSJ reports

Australia sells AUD 1.0bln 1.25% 2032 AGBs: b/c 4.01x, average yield 4.7406%

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

China

Beijing Biostar Pharmaceuticals (5263 HK) - Co. plans to issue 25mln new shares at HKD 4.00/shr. (Newswires)

Cornerstone Technologies (8391 HK) - Co. said Spark will acquire six EV charging locations with 24 charging points in Thailand. (Newswires)

Guiyang Xintian Pharmaceutical (002873 CH) - Co. said a key shareholder plans to sell up to a 3% stake over the next three months. (Newswires)

InnoCare (9969 HK) – Co. announces the approval of a Phase 2 clinical trial of its TYK2 inhibitor for Sjogren's Syndrome in China. (Newswires)

Lotus Horizon Holdings (6063 HK) - Co. expects FY net loss of HKD 3.5mln and rev. to fall about 13.3%. (Newswires)

Context

Meanwhile, InnoCare's approval for a Phase 2 clinical trial could lead to positive investor sentiment in the biotech space, while Lotus Horizon's anticipated net loss highlights operational struggles, potentially impacting investor confidence across the sector.

Related headlines

The whole workspace, free to try.

Try it free